Cargando…

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology

The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise...

Descripción completa

Detalles Bibliográficos
Autores principales: van Harten, WH, Retèl, VP
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130332/
https://www.ncbi.nlm.nih.gov/pubmed/27994642
http://dx.doi.org/10.3332/ecancer.2016.686
_version_ 1782470715088306176
author van Harten, WH
Retèl, VP
author_facet van Harten, WH
Retèl, VP
author_sort van Harten, WH
collection PubMed
description The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership. Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement.
format Online
Article
Text
id pubmed-5130332
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-51303322016-12-19 Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology van Harten, WH Retèl, VP Ecancermedicalscience Policy The Organisation of European Cancer Institutes OECI working group on Health Economics and Cost Benefit in Oncology suggests four actions that are needed to improve alignment and integration between clinicians, researchers, and Health Technology Assessment (HTA) experts and agencies: 1) HTA expertise is necessary close to or within the comprehensive cancer centres (CCC); 2) HTA expertise should be physically present throughout the translational research process; 3) Appropriate knowledge is necessary within the research staff; 4) Close cooperation between translational researchers, clinicians, and health economists guarantees clinical ownership. Fulfilling these conditions may help the translational research field in oncology to interact with agencies and efficiently move innovative technologies through the translational research stages into that of implementation and diffusion. This brings innovative treatments faster to the patient with a greater chance of reimbursement. Cancer Intelligence 2016-10-28 /pmc/articles/PMC5130332/ /pubmed/27994642 http://dx.doi.org/10.3332/ecancer.2016.686 Text en © the authors; licensee ecancermedicalscience. http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Policy
van Harten, WH
Retèl, VP
Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
title Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
title_full Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
title_fullStr Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
title_full_unstemmed Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
title_short Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
title_sort close cooperation with health technology assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
topic Policy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130332/
https://www.ncbi.nlm.nih.gov/pubmed/27994642
http://dx.doi.org/10.3332/ecancer.2016.686
work_keys_str_mv AT vanhartenwh closecooperationwithhealthtechnologyassessmentexpertiseiscrucialforimplementationandultimatelyreimbursementofinnovationsinoncology
AT retelvp closecooperationwithhealthtechnologyassessmentexpertiseiscrucialforimplementationandultimatelyreimbursementofinnovationsinoncology